A recall for EpiPens will now extend to Asia, Europe, North America, and South America:
Generic drugmaker Mylan NV said on Friday that its manufacturing partner for EpiPen devices had expanded a recall of the life-saving allergy shot in the United States and other markets.
The announcement comes a week after Mylan said it had recalled about 81,000 EpiPen devices in countries outside the United States following two reports of the company's allergy treatment failing to work in emergencies.
[Ed. Note: This recall is limited to some lot numbers distributed in late 2015 and early-to-mid 2016. More information at the US FDA website.]
(Score: 0) by Anonymous Coward on Tuesday April 04 2017, @01:23AM
No, monopolies aren’t illegal. But if you’re a monopoly and use that position to try to shut potential competitors out of the market, that is market power abuse. One example of market power abuse is by attempting to price competitors out of the market, as the GGP says Mylan could potentially do to other pharmaceutical companies trying to market the old EpiPen design.